CJC-1295 vs MGF
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone and is almost universally used in combination with a GHRP like Ipamorelin to produce a more physiological GH pulse.
Full profileMGF
MGF (Mechano Growth Factor) is a splice variant of IGF-1 produced locally in muscle tissue in response to mechanical loading (exercise, especially eccentric loading). Unlike circulating IGF-1 which is produced primarily by the liver, MGF is generated within the muscle itself and acts locally to activate satellite cells (muscle stem cells) — the cells responsible for muscle repair, growth, and adaptation. It is considered the primary local anabolic signal generated by resistance training.
Full profile| CJC-1295 | MGF | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 DAC, CJC-1295 without DAC (Mod GRF 1-29), Modified GRF 1-29 | Mechano Growth Factor, IGF-1Ec, Insulin-like Growth Factor splice variant |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 100mcg–300mcg mcg, once daily (Mod GRF) or twice weekly (DAC version) | 100mcg–300mcg mcg, Post-workout (within 30–60 minutes of training), 3–4x weekly |
| Administration | Subcutaneous injection (most common), Intramuscular injection | Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution) |
| Key side effects | Water retention (especially early in protocol), Tingling or numbness in extremities, Injection site redness, Flushing (transient, shortly after injection) | Localized muscle swelling at injection site (normal response), Hypoglycemia (less pronounced than IGF-1 DES but present), Very short half-life means side effects are brief, Potential overuse injury if post-workout injection is used consistently without adequate recovery |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: CJC-1295 is research-stage, while MGF is preclinical only.
- Administration: CJC-1295 — Subcutaneous injection (most common), Intramuscular injection; MGF — Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution).
- Frequency: CJC-1295 is typically once daily (Mod GRF) or twice weekly (DAC version); MGF is Post-workout (within 30–60 minutes of training), 3–4x weekly.
- Research depth: this profile cites 2 sources for CJC-1295 vs 3 for MGF.
How each works
CJC-1295
Studies have demonstrated that CJC-1295 significantly increases plasma GH and IGF-1 levels. The DAC (Drug Affinity Complex) version extends the half-life to approximately 6–8 days via albumin binding, while Mod GRF 1-29 has a much shorter half-life (~30 minutes) and is dosed more acutely. Research in adults with GH deficiency has shown improved body composition and metabolic markers.
MGF
MGF is encoded by the IGF-1 gene but produced via alternative splicing that generates a unique 49-amino acid C-terminal E-peptide (Ec peptide). The Ec peptide has distinct biological activity from the IGF-1 domain — it directly activates satellite cell proliferation through a receptor pathway separate from the standard IGF-1R. Studies in rodents show that local MGF injection produces significant muscle hypertrophy in the injected limb without systemic IGF-1 elevation. MGF expression spikes within 30 minutes of resistance exercise and declines over 24–48 hours — aligning precisely with the post-exercise anabolic window.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.